Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | SLC22A16 | Q86VW1 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | HRH1 | P35367 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | RECQL | P46063 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5357430 | 0.89 | SMN1; SMN2 (0.35) | SMN1; SMN2 | |
| SCHEMBL10604508 | 0.87 | SMN1; SMN2 (0.42) | SMN1; SMN2SLC22A16MEN1KMT2ACYP1A2 | |
| SCHEMBL10606120 | 0.87 | SMN1; SMN2 (0.42) | SMN1; SMN2SLC22A16MEN1KMT2ACYP1A2 | |
| SCHEMBL10602657 | 0.87 | SMN1; SMN2 (0.42) | SMN1; SMN2SLC22A16MEN1KMT2ACYP1A2 | |
| Zinc Ion SCHEMBL10604220 | 0.87 | SMN1; SMN2 (0.42) | SMN1; SMN2SLC22A16MEN1KMT2ACYP1A2 | |
| SCHEMBL27282999 | 0.86 | SMN1; SMN2 (0.37) | SMN1; SMN2SLC22A16MEN1KMT2ACYP1A2 | |
| SCHEMBL14739090 | 0.79 | MEN1 (0.35) | SMN1; SMN2MEN1KMT2ACYP1A2HRH1 | |
| SCHEMBL8861292 | 0.79 | SMN1; SMN2 (0.56) | SMN1; SMN2MEN1KMT2AMAPTLMNA | |
| SCHEMBL192296 | 0.79 | MEN1 (0.39) | SMN1; SMN2SLC22A16MEN1KMT2ACYP1A2 | |
| SCHEMBL5255308 | 0.78 | MEN1 (0.34) | SMN1; SMN2SLC22A16MEN1KMT2ACYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 626 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240156790-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR MODULATING FERROPTOSIS AND TREATING EXCITOTOXIC DISORDERS | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK | 2024-05-16 | — | — | US | claimed |
| US-20240115499-A1 | DHA and Choline Emulsion | CAPSUGEL BELGIUM NV (BE) | 2024-04-11 | — | — | US | claimed |
| EP-4347605-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR MODULATING FERROPTOSIS AND TREATING EXCITOTOXIC DISORDERS | The Trustees of Columbia University in the City of New York (US) | 2024-04-10 | — | — | EP | claimed |
| EP-4319759-A1 | 1-METHYLXANTHINE-BASED BIOACTIVE COMPOSITION AND METHOD OF USE THEREOF | Ingenious Ingredients, LP (US) | 2024-02-14 | — | — | EP | claimed |
| EP-4313056-A1 | THE USE OF PARAXANTHINE TO IMPROVE PERFORMANCE IN VIDEO GAMERS | PX ING, LLC (US) | 2024-02-07 | — | — | EP | claimed |
| EP-4312801-A1 | PARAXANTHINE-BASED COMPOSITIONS FOR PROMOTING WEIGHT LOSS | PX ING, LLC (US) | 2024-02-07 | — | — | EP | claimed |
| WO-2023173111-A2 | INTRA-DOSAGE FORM COATINGS AND APPLICATIONS THEREOF | BALCHEM CORPORATION (US) | 2023-09-14 | — | — | WO | claimed |
| US-20230217977-A1 | DIETARY CHOLINE SUPPLEMENTATION TO REDUCE TUMOR VOLUME AND ENHANCE COGNITIVE RESPONSE DURING CANCER TREATMENT | NATIONAL INSTITUTES OF HEALTH | 2023-07-13 | — | — | US | claimed |
| WO-2023064511-A9 | PARAXANTHINE-BASED BIOACTIVE COMPOSITION AND METHOD OF USE THEREOF | Ingenious Ingredients, LP (US) | 2023-06-08 | — | — | WO | claimed |
| WO-2023084508-A1 | COGNITIVE ENHANCING DIETARY SUPPLEMENT | ZEEVI INON MOSHE (IL) | 2023-05-19 | — | — | WO | claimed |
| US-20040043013-A1 | Metabolic uncoupling therapy | MCCLEARY EDWARD LARRY (US) | 2004-03-04 | — | — | US | claimed |
| WO-2002013838-A1 | SEAL-OIL-BASED PHARMACEUTICAL, COSMETIC, DERMO-COSMETIC, HYGIENE, ALIMENTARY AND PARA-ALIMENTARY (FOOD-SUPPLEMENTS) PRODUCTS; THEIR METHODS OF PREPARATION; THEIR USES AS PREVENTIVE AND/OR AS THERAPEUTIC AGENTS | FUNDAÇAO ESSPRIT-ICARUS (FUNDAÇAO EUROPEIA DE INVESTIGAÇAO MEDICA), NGO; IPSS. (PT) | 2002-02-21 | — | — | WO | claimed |
| US-5250719-A | Process for the preparation of L-α-glycerylphosphoryl-choline and of L-α-glycerylphosphorylethanolamine | PRIME EUROPEAN THERAPEUTICALS S.P.A. (IT) | 1993-10-05 | — | — | US | claimed |
| EP-0217765-B1 | PROCESS FOR THE PREPARATION OF L-ALPHA-GLYCERYLPHOSPHORYLCHOLINE, L-ALPHA-GLYCERYLPHOSPHORYLETHANOLAMINE FROM CRUDE AND/OR DEOLEATED LECITHINS | ISTITUTO CHEMIOTERAPICO ITALIANO FINE CHEMICALS S.p.A. (IT) | 1990-08-16 | — | — | EP | claimed |
| EP-0186803-B1 | DIACYLDERIVATIVES OF GLYCERYLPHOSPHORYLCHOLINE HAVING THERAPEUTICAL ACTIVITY, A PROCESS FOR THEIR PREPARATION AND RELATED PHARMACEUTICAL COMPOSITIONS | NEOPHARMED S.p.A. (IT) | 1989-09-20 | — | — | EP | claimed |
| US-4824978-A | Complexes of glycerylphosphorylcholine | NEOPHARMED SPA (IT) | 1989-04-25 | — | — | US | claimed |
| US-4699901-A | Diacyl derivatives of glycerylphosphorylcholine, their preparation, and antihyperlipidemic compositions | NEOPHARMED SPA (IT) | 1987-10-13 | — | — | US | claimed |
| EP-0217765-A2 | Process for the preparation of L-alpha-glycerylphosphorylcholine, L-alpha-glycerylphosphorylethanolamine from crude and/or deoleated lecithins | ISTITUTO CHEMIOTERAPICO ITALIANO FINE CHEMICALS S.p.A. (IT) | 1987-04-08 | — | — | EP | claimed |
| EP-0186803-A2 | Diacylderivatives of glycerylphosphorylcholine having therapeutical activity, a process for their preparation and related pharmaceutical compositions | NEOPHARMED S.p.A. (IT) | 1986-07-09 | — | — | EP | claimed |
| US-4130571-A | Process for preparing 1,2-diacyl-3-glycerylphosphorylcholines | NIPPON SHOJI KAISHA, LTD. (JP) | 1978-12-19 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240156790-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR MODULATING FERROPTOSIS AND TREATING EXCITOTOXIC DISORDERS | AIFM2, GPX1, SLC7A11 | SMN1; SMN2 311/4885SLC22A16 433/4885MEN1 2584/4885 |
| US-20240115499-A1 | DHA and Choline Emulsion | LIPA, CHAT, PHOSPHO1 | SMN1; SMN2 863/4885SLC22A16 864/4885MEN1 2703/4885 |
| US-20230217977-A1 | DIETARY CHOLINE SUPPLEMENTATION TO REDUCE TUMOR VOLUME AND ENHANCE COGNITIVE RESPONSE DURING CANCER TREATMENT | CHAT, CHKA, CHKB | SMN1; SMN2 2084/4885SLC22A16 1592/4885MEN1 218/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.